Literature DB >> 3742604

In vivo cytotoxic responses induced by allogeneic normal and neoplastic cells in mice: relative lack of immunogenicity of B16 melanoma cells.

M P Ashley, I Kotlarski.   

Abstract

It has been previously reported from this laboratory that the C57BL/6 melanoma B16 will grow in allogeneic mice provided that donor-derived passenger leukocytes are first removed by in vitro passage of the tumor cells. In this paper we report that allogeneic and syngeneic mice support similar survival of [125I]iododeoxyuridine-labeled B16 cells (125I-B16 cells) as indicated by whole-body retention of 125I. B16 failed to induce the early cytotoxic response which was induced by semiallogeneic peritoneal cells (PC) and by two other allogeneic tumors (EL4 lymphoma and MC-2 sarcoma). They were nevertheless rapidly destroyed by the response induced by PC or EL4. B16 did show some immunogenicity as indicated by regression of some primary B16 tumors (45% ip and the majority of footpad tumors) and by the slow cytotoxic response to secondary 125I-B16 challenge following preimmunization with live or irradiated B16 cells. An equivalent response was induced by preimmunization with a 100-fold lower dose of PC. These findings are discussed in relation to the requirement for inductive stimuli, in addition to antigen, for the stimulation of in vivo cytotoxic responses.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3742604     DOI: 10.1016/0008-8749(86)90194-2

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  2 in total

1.  Multiple murine BRaf(V600E) melanoma cell lines with sensitivity to PLX4032.

Authors:  Molly H Jenkins; Shannon M Steinberg; Matthew P Alexander; Jan L Fisher; Marc S Ernstoff; Mary Jo Turk; David W Mullins; Constance E Brinckerhoff
Journal:  Pigment Cell Melanoma Res       Date:  2014-03-06       Impact factor: 4.693

2.  Increased projection of MHC and tumor antigens in murine B16-BL6 melanoma induced by hydrostatic pressure and chemical crosslinking.

Authors:  V Ramakrishna; A Eisenthal; Y Skornick; M Shinitzky
Journal:  Cancer Immunol Immunother       Date:  1993-05       Impact factor: 6.968

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.